← Leaderboards
David I Watkins
George Washington University
$75,196,434
Attributed
$75,346,233
Total exposure
106
Grants
78
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.8M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$86,700,391 · 107
By mechanism
R01$24,208,026 · 6
R24$17,886,526 · 4
P01$17,868,007 · 4
P51$12,655,978 · 81
R37$7,120,140 · 1
R42$3,266,185 · 1
Top collaborators
- Jonah B. Sacha1 shared
Others in their field
Top investigators on “Macaca Mulatta”
- Barton F Haynes · Duke University$291,595,855
- Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
- Richard A Gibbs · Baylor College Of Medicine$82,928,769
- Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
- Rama Rao Amara · Emory University$54,145,017
- Louis J. Picker · Oregon Health And Science University$48,793,738
Research focus
Macaca MulattaMacacaVaccinesViralHiv VaccineAnimalsVirusVaccinatedEpitopesResponseImmune ResponseInfectionGrantT-LymphocyteFundingResearch PersonnelVirus ReplicationCd8b1 GeneSourceServicesUnited States National Institutes Of HealthResourcesPeptidesAlleles
Grant awards (197)
The functional significance of CTL escape$867,514
R01 · FY2024 · AI · contact PI
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?$978,679
R42 · FY2023 · AI · contact PI
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?$988,498
R42 · FY2022 · AI · contact PI
The functional significance of CTL escape$888,436
R01 · FY2022 · AI · contact PI
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?$999,410
R42 · FY2021 · AI · contact PI
The functional significance of CTL escape$917,023
R01 · FY2021 · AI · contact PI
The functional significance of CTL escape$699,291
R01 · FY2020 · AI · contact PI
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?$299,598
R42 · FY2020 · AI
The functional significance of CTL escape$267,023
R01 · FY2020 · AI · contact PI
The functional significance of CTL escape$948,180
R01 · FY2019 · AI · contact PI
Rapid Development of a Highly Specific Dengue Diagnostic Test$299,938
R41 · FY2019 · AI · contact PI
Can vaccine-induced CD8 T cells prevent chronic phase AIDS virus replication?$598,886
R01 · FY2018 · AI · contact PI
Rapid development of a Zika-specific diagnostic test$299,890
R41 · FY2018 · AI · contact PI
The Functional Significance of CTL Escape$719,626
R37 · FY2017 · AI · contact PI
Can vaccine-induced CD8 T cells prevent chronic phase AIDS virus replication?$565,692
R01 · FY2017 · AI · contact PI
Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development$3,146,402
P01 · FY2016 · AI · contact PI
Protective Immunity$2,321,479
P01 · FY2016 · AI · contact PI
The Functional Significance of CTL Escape$714,288
R37 · FY2016 · AI · contact PI
Can vaccine-induced CD8 T cells prevent chronic phase AIDS virus replication?$529,979
R01 · FY2016 · AI · contact PI
Administrative Core$72,451
P01 · FY2016 · AI · contact PI
Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development$1,956,887
P01 · FY2015 · AI · contact PI
Protective Immunity$840,487
P01 · FY2015 · AI · contact PI
The Functional Significance of CTL Escape$733,814
R37 · FY2015 · AI · contact PI
Can vaccine-induced CD8 T cells prevent chronic phase AIDS virus replication?$619,351
R01 · FY2015 · AI · contact PI
Administrative Core$73,300
P01 · FY2015 · AI · contact PI
Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development$1,946,966
P01 · FY2014 · AI · contact PI
Protective Immunity$847,269
P01 · FY2014 · AI · contact PI
The Functional Significance of CTL Escape$752,776
R37 · FY2014 · AI · contact PI
Can vaccine-induced CD8 T cells prevent chronic phase AIDS virus replication?$544,921
R01 · FY2014 · AI · contact PI
Administrative Core$351,908
P01 · FY2014 · AI · contact PI
Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development$2,145,532
P01 · FY2013 · AI · contact PI
MHC-bound, SIV-derived, CTL and HTL Epitopes$1,060,013
R24 · FY2013 · OD · contact PI
Protective Immunity$973,903
P01 · FY2013 · AI · contact PI
The Functional Significance of CTL Escape$739,662
R37 · FY2013 · AI · contact PI
MHC Typing of Macaques Used in AIDS Research$638,732
R24 · FY2013 · OD · contact PI
Administrative Core$82,539
P01 · FY2013 · AI · contact PI
Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development$2,158,371
P01 · FY2012 · AI · contact PI
MHC-bound, SIV-derived, CTL and HTL Epitopes$1,114,629
R24 · FY2012 · OD · contact PI
MHC Typing of Macaques Used in AIDS Research$671,766
R24 · FY2012 · OD · contact PI
The Functional Significance of CTL Escape$560,203
R37 · FY2012 · AI · contact PI
Protective Immunity$514,502
P01 · FY2012 · AI · contact PI
SIV-specific Mamu-E-restricted CD8+ T cells$216,353
R21 · FY2012 · AI · contact PI
Administrative Core$82,383
P01 · FY2012 · AI · contact PI
MHC-bound, SIV-derived, CTL and HTL Epitopes$763,872
R24 · FY2011 · RR · contact PI
A Novel, Logical Approach to HIV Vaccine Development$693,112
R56 · FY2011 · AI · contact PI
The Functional Significance of CTL Escape$663,171
R37 · FY2011 · AI · contact PI
MHC Typing of Macaques Used in AIDS Research$659,249
R24 · FY2011 · RR · contact PI
DEVELOPMENT OF IMMUNE MONITORING REAGENTS AND MHC TYPING TECHNOLOGIES$631,487
P51 · FY2011 · RR · contact PI
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$476,591
P51 · FY2011 · RR · contact PI
MINIGENE VACCINATION WITH EARLY PRESENTED VIRAL PROTEINSAIDS RELATED RESEARCH$381,254
P51 · FY2011 · RR · contact PI
MHC-bound, SIV-derived, CTL and HTL Epitopes$350,757
R24 · FY2011 · RR · contact PI
FUNCTIONAL SIGNIFICANCE OF CTL ESCAPE$321,692
P51 · FY2011 · RR · contact PI
MHC TYPING OF MACAQUES USED IN AIDS RESEARCH$285,918
P51 · FY2011 · RR · contact PI
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT$238,342
P51 · FY2011 · RR · contact PI
SIV-specific Mamu-E-restricted CD8+ T cells$204,339
R21 · FY2011 · AI · contact PI
PROTECTIVE EFFICACY OF MERCK AD5 PRIME/BOOST AGAINST MUCOSAL CHALLENGE$178,687
P51 · FY2011 · RR · contact PI
IMMUNOGENICITY AND PROTECTION OF LIVE ATTENUATED SIV239 DELTA NEF IN RHESUS$119,125
P51 · FY2011 · RR · contact PI
VACCINE REGIMENS TO INDUCE CD4+ AND CD8+ T CELLS AGAINST SIV EPITOPES$95,337
P51 · FY2011 · RR · contact PI
CRYPTIC ORFS AS A VACCINE FOR HIV$59,562
P51 · FY2011 · RR · contact PI
The Functional Significance of CTL Escape$56,489
R37 · FY2011 · AI · contact PI
A Novel, Logical Approach to HIV Vaccine Development$26,228
R56 · FY2011 · AI · contact PI
MHC-bound, SIV-derived, CTL and HTL Epitopes$1,125,888
R24 · FY2010 · RR · contact PI
Minigene Vaccination with Early Presented Viral Proteins$872,872
R01 · FY2010 · AI · contact PI
The Functional Significance of CTL Escape$714,519
R37 · FY2010 · AI · contact PI
MHC Typing of Macaques Used in AIDS Research$665,908
R24 · FY2010 · RR · contact PI
Vif-specific CD8 responses in individuals that control HIV replication$159,090
R21 · FY2010 · AI · contact PI
Cryptic ORFs as a vaccine for HIV$140,408
R21 · FY2010 · AI · contact PI
WNPRC IMMUNOLOGY & VIROLOGY UNIT$103,269
P51 · FY2010 · RR · contact PI
DEVELOPMENT OF IMMUNE MONITORING REAGENTS AND MHC TYPING TECHNOLOGIES$51,635
P51 · FY2010 · RR · contact PI
CRYPTIC ORFS AS A VACCINE FOR HIV$51,635
P51 · FY2010 · RR · contact PI
WNPRC ELITE CONTROLLER RESOURCE$51,635
P51 · FY2010 · RR · contact PI
DEVELOPMENT OF A LOW DOSE CHALLENGE MODEL USING SIVSME660 IN RHESUS MACAQUES$51,635
P51 · FY2010 · RR · contact PI
VACCINE REGIMENS TO INDUCE CD4+ AND CD8+ T CELLS AGAINST SIV EPITOPES$51,635
P51 · FY2010 · RR · contact PI
PROTECTIVE CAPABILITIES OF FOUR BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES$51,635
P51 · FY2010 · RR · contact PI
MINIGENE VACCINATION WITH EARLY PRESENTED VIRAL PROTEINSAIDS RELATED RESEARCH$51,635
P51 · FY2010 · RR · contact PI
FUNCTIONAL SIGNIFICANCE OF CTL ESCAPE$51,635
P51 · FY2010 · RR · contact PI
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT$51,635
P51 · FY2010 · RR · contact PI
IMMUNOGENICITY AND PROTECTION OF LIVE ATTENUATED SIV239 DELTA NEF IN RHESUS$51,635
P51 · FY2010 · RR · contact PI
MHC TYPING OF MACAQUES USED IN AIDS RESEARCH$51,635
P51 · FY2010 · RR · contact PI
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$51,635
P51 · FY2010 · RR · contact PI
The Functional Significance of CTL Escape$730,434
R37 · FY2009 · AI · contact PI
MHC-bound, SIV-derived, CTL & HTL Epitopes$707,662
R24 · FY2009 · RR · contact PI
Minigene Vaccination with Early Presented Viral Proteins$680,829
R01 · FY2009 · AI · contact PI
MHC Typing of Macaques Used in AIDS Research$665,742
R24 · FY2009 · RR · contact PI
A Novel, Logical Approach to HIV Vaccine Development$532,538
R01 · FY2009 · AI · contact PI
WNPRC IMMUNOLOGY & VIROLOGY UNIT$393,180
P51 · FY2009 · RR · contact PI
Cryptic ORFs as a vaccine for HIV$245,886
R21 · FY2009 · AI · contact PI
Vaccine Regimens to Induce CD4+ and CD8+ T cells against SIV Epitopes$203,635
R21 · FY2009 · AI · contact PI
VACCINE REGIMENS TO INDUCE CD4+ AND CD8+ T CELLS AGAINST SIV EPITOPES$196,590
P51 · FY2009 · RR · contact PI
PROTECTIVE CAPABILITIES OF FOUR BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES$196,590
P51 · FY2009 · RR · contact PI
MINIGENE VACCINATION WITH EARLY PRESENTED VIRAL PROTEINSAIDS RELATED RESEARCH$196,590
P51 · FY2009 · RR · contact PI
THE FUNCTIONAL SIGNIFICANCE OF CTL ESCAPE$196,590
P51 · FY2009 · RR · contact PI
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT$196,590
P51 · FY2009 · RR · contact PI
IMMUNOGENICITY AND PROTECTION OF LIVE ATTENUATED SIV239 DELTA NEF IN RHESUS$196,590
P51 · FY2009 · RR · contact PI
DEVELOPMENT OF IMMUNE MONITORING REAGENTS AND MHC TYPING TECHNOLOGIES$196,590
P51 · FY2009 · RR · contact PI
WNPRC ELITE CONTROLLER RESOURCE$196,590
P51 · FY2009 · RR · contact PI
DEVELOPMENT OF A LOW DOSE CHALLENGE MODEL USING SIVSME660 IN RHESUS MACAQUES$196,590
P51 · FY2009 · RR · contact PI
MHC TYPING OF MACAQUES USED IN AIDS RESEARCH$196,590
P51 · FY2009 · RR · contact PI
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$196,590
P51 · FY2009 · RR · contact PI
Vif-specific CD8 responses in individuals that control HIV replication$172,425
R21 · FY2009 · AI · contact PI
A Novel, Logical Approach to HIV Vaccine Development$943,623
R01 · FY2008 · AI · contact PI
The Functional Significance of CTL Escape$735,158
R37 · FY2008 · AI · contact PI
MHC-bound, SIV-derived, CTL & HTL Epitopes$687,869
R24 · FY2008 · RR · contact PI
Minigene Vaccination with Early Presented Viral Proteins$652,374
R01 · FY2008 · AI · contact PI
MHC Typing of Macaques used in AIDS Research$586,792
R24 · FY2008 · RR · contact PI
WNPRC IMMUNOLOGY & VIROLOGY UNIT$491,487
P51 · FY2008 · RR · contact PI
Vaccine Regimens to Induce CD4+ and CD8+ T cells against SIV Epitopes$179,874
R21 · FY2008 · AI · contact PI
DEVELOPMENT OF IMMUNE MONITORING REAGENTS AND MHC TYPING TECHNOLOGIES$163,829
P51 · FY2008 · RR · contact PI
PROTECTIVE CAPABILITIES OF FOUR BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES$163,829
P51 · FY2008 · RR · contact PI
MINIGENE VACCINATION WITH EARLY PRESENTED VIRAL PROTEINSAIDS RELATED RESEARCH$163,829
P51 · FY2008 · RR · contact PI
MHC TYPING OF MACAQUES USED IN AIDS RESEARCH$163,829
P51 · FY2008 · RR · contact PI
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$163,829
P51 · FY2008 · RR · contact PI
THE FUNCTIONAL SIGNIFICANCE OF CTL ESCAPE$163,829
P51 · FY2008 · RR · contact PI
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT$163,829
P51 · FY2008 · RR · contact PI
IMMUNOGENICITY AND PROTECTION OF LIVE ATTENUATED SIV239 DELTA NEF IN RHESUS$163,829
P51 · FY2008 · RR · contact PI
A Novel, Logical Approach to HIV Vaccine Development$1,041,267
R01 · FY2007 · AI · contact PI
The Functional Significance of Cytotoxic T Lymphocyte Escape$639,000
R01 · FY2007 · AI · contact PI
MHC Typing of Macaques used in AIDS Research$582,267
R24 · FY2007 · RR · contact PI
Minigene Vaccination with Early Presented Viral Proteins$581,321
R01 · FY2007 · AI · contact PI
MHC-bound, SIV-derived, CTL & HTL Epitopes$574,647
R24 · FY2007 · RR · contact PI
WNPRC IMMUNOLOGY & VIROLOGY UNIT$536,055
P51 · FY2007 · RR · contact PI
THE FUNCTIONAL SIGNIFICANCE OF CTL ESCAPE$214,423
P51 · FY2007 · RR · contact PI
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT$214,423
P51 · FY2007 · RR · contact PI
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$211,929
P51 · FY2007 · RR · contact PI
MHC TYPING FOR AIDS RESEARCH$211,927
P51 · FY2007 · RR · contact PI
IMMUNOGENICITY AND PROTECTION OF LIVE ATTENUATED SIV239 DELTA NEF IN RHESUS$207,938
P51 · FY2007 · RR · contact PI
DEVELOPMENT OF IMMUNE MONITORING REAGENTS AND MHC TYPING TECHNOLOGIES$125,933
P51 · FY2007 · RR · contact PI
A Novel, Logical Approach to HIV Vaccine Development$950,584
R01 · FY2006 · AI · contact PI
The Functional Significance of CTL Escape$867,756
R01 · FY2006 · AI · contact PI
MHC Typing of Macaques used in AIDS Research$583,159
R24 · FY2006 · RR · contact PI
MHC-bound, SIV-derived, CTL & HTL Epitopes$575,075
R24 · FY2006 · RR · contact PI
MHC TYPING FOR AIDS RESEARCH$163,288
P51 · FY2006 · RR · contact PI
THE FUNCTIONAL SIGNIFICANCE OF CTL ESCAPE$163,288
P51 · FY2006 · RR · contact PI
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT$163,288
P51 · FY2006 · RR · contact PI
DEFINING CORRELATES OF PROTECTION IN DELTA NEF-VACCINEES$163,288
P51 · FY2006 · RR · contact PI
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$163,288
P51 · FY2006 · RR · contact PI
CTL-BASED VACCINES FOR THE AIDS VIRUS$163,288
P51 · FY2006 · RR · contact PI
STRATEGIES OF IMMUNE EVASION IN AIDS$134,807
P51 · FY2006 · RR · contact PI
DEVELOPMENT OF IMMUNE MONITORING REAGENTS AND MHC TYPING TECHNOLOGIES$81,644
P51 · FY2006 · RR · contact PI
The Functional Significance of CTL Escape$867,038
R01 · FY2005 · AI
A Novel, Logical Approach to HIV Vaccine Development$605,815
R01 · FY2005 · AI
MHC-bound, SIV-derived, CTL &HTL Epitopes$584,733
R24 · FY2005 · RR
MHC Typing of Macaques used in AIDS Research$580,584
R24 · FY2005 · RR
WNPRC IMMUNOGENETICS &VIROLOGY SERVICES$310,973
P51 · FY2005 · RR
A Novel Chlamydial Vector for HIV Vaccine Development$282,700
R21 · FY2005 · AI
CTL-BASED VACCINES FOR THE AIDS VIRUS$46,225
P51 · FY2005 · RR
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$45,973
P51 · FY2005 · RR
DEFINING CORRELATES OF PROTECTION IN DELTA NEF-VACCINATED MACAQUES$45,973
P51 · FY2005 · RR
MHC TYPING OF MACAQUES USED IN AIDS RESEARCH$45,973
P51 · FY2005 · RR
MAJOR HISTOCOMPATIBILITY CLASS I ALLELES OF CYNOMOLGUS MACAQUES$45,973
P51 · FY2005 · RR
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT$856,761
R01 · FY2004 · AI
The Functional Significance of CTL Escape$679,982
R01 · FY2004 · AI
MHC Typing of Macaques used in AIDS Research$575,051
R24 · FY2004 · RR
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$568,404
R24 · FY2004 · RR
WNRPC GENETICS RESOURCES$301,227
P51 · FY2004 · RR
A Novel Chlamydial Vector for HIV Vaccine Development$236,851
R21 · FY2004 · AI
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$150,572
P51 · FY2004 · RR
CTL-BASED VACCINES FOR THE AIDS VIRUS$150,572
P51 · FY2004 · RR
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT$931,391
R01 · FY2003 · AI
The Functional Significance of CTL Escape$661,445
R01 · FY2003 · AI
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$551,851
R24 · FY2003 · RR
MHC TYPING OF MACAQUES USED IN AIDS RESEARCH$490,135
R24 · FY2003 · RR
CTL-BASED VACCINES FOR THE AIDS VIRUS$440,507
R01 · FY2003 · AI
MACAQUES MHC AND MOTIF ANALYSES$23,698
P51 · FY2003 · RR
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT$944,842
R01 · FY2002 · AI
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$535,778
R24 · FY2002 · RR
MHC TYPING OF MACAQUES USED IN AIDS RESEARCH$475,913
R24 · FY2002 · RR
CTL-BASED VACCINES FOR THE AIDS VIRUS$369,168
R01 · FY2002 · AI
STUDY OF MHC &CTL IN OPIATE-DEPENDENT MONKEYS WITH AIDS$338,829
R01 · FY2002 · DA
QUANTITATIVE ANALYSIS OF IMMUNITY TO VIRAL IMMUNOGENS$0
P01 · FY2002 · AG
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT$786,175
R01 · FY2001 · AI
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$520,171
R24 · FY2001 · RR
MHC TYPING OF MACAQUES USED IN AIDS RESEARCH$484,860
R24 · FY2001 · RR
CTL-BASED VACCINES FOR THE AIDS VIRUS$412,690
R01 · FY2001 · AI
STUDY OF MHC &CTL IN OPIATE-DEPENDENT MONKEYS WITH AIDS$328,960
R01 · FY2001 · DA
UNUSUAL POST SPECIES EVOLUTION OF MHC CLASS I LOCI IN NEW WORLD PRIMATES$0
P51 · FY2001 · RR
GAG CYTOTOXIC T LYMPHOCYTES IN SIV: TETRAMERIC MHC CLASS I/PEPTIDE COMPLEX STAIN$0
P51 · FY2001 · RR
SIV &SHIV CTL EPITOPES IDENTIFIED IN MACAQUES$0
P51 · FY2001 · RR
TWO DIFFERENT PRIMATE SPECIES EXPRESS AN IDENTICAL FUNCTIONAL MHC CLASS I ALLELE$0
P51 · FY2001 · RR
PEPTIDE MOTIF OF MHC CLASS I (MAMU A*01) BINDS IMMUNODOMINANT CTL SIV EPITOPE$0
P51 · FY2001 · RR
RHESUS MONKEY ANALOG OF HLA G IS EXPRESSED IN VILLOUS SYNCYTIOTROPHOBLAST$0
P51 · FY2001 · RR
MHC E LOCUS: ANCIENT &WELL CONSERVED PRIMATE CLASS I HISTOCOMPATIBILITY GENES$0
P51 · FY2001 · RR
QUANTITATIVE ANALYSIS OF IMMUNITY TO VIRAL IMMUNOGENS$0
P01 · FY2001 · AG
MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES$505,019
R24 · FY2000 · RR
CTL-BASED VACCINES FOR THE AIDS VIRUS$435,384
R01 · FY2000 · AI
QUANTITATIVE ANALYSIS OF IMMUNITY TO VIRAL IMMUNOGENS$353,628
P01 · FY2000 · AG
STUDY OF MHC &CTL IN OPIATE-DEPENDENT MONKEYS WITH AIDS$319,379
R01 · FY2000 · DA
QUANTITATION OF T CELL RESPONSES TO VACCINATION$272,800
R21 · FY2000 · AI
VIRUS SPECIFIC CTL RESPONSES SELECT FOR AMINO ACID VARIATION IN SIV ENV &NEF$139,393
P51 · FY2000 · RR
RAPID &SLOW PROGESSORS DIFFER BY SINGLE MHC CLASS I HAPLOTYPE IN SIV MACAQUES$139,393
P51 · FY2000 · RR
MHC CLASS I GENES IN PRIMATES COEVOLUTION W/ PATHOGENS: SIV$139,393
P51 · FY2000 · RR
RHESUS MONKEY MHC CLASS IB EXPRESSION TISSUE DISTRIBUTION OF MAMU AG MRNA$70,790
P51 · FY2000 · RR
MHC CLASS I GENES IN COTTON TOP TAMARIN, EVOLVE BY PROCESS OF LOCI TURNOVER$70,790
P51 · FY2000 · RR
3 DIFFERENT MHC CLASS I MOLECULES BIND SAME CTL EPITOPE OF INFLUENZA VIRUS$70,790
P51 · FY2000 · RR
EVOLUTION OF NOVEL NON CLASSICAL MHC CLASS I GENE IN OLD WORLD PRIMATES$70,790
P51 · FY2000 · RR
EBV/SIV CHIMERA VECTORS FOR AIDS VIRUS VACCINATION$62,000
R03 · FY2000 · AI
STUDY OF MHC &CTL IN OPIATE DEPENDENT MONKEYS WITH AIDS$21,200
R01 · FY2000 · DA